{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:30:13Z","timestamp":1790771413973,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["257505"],"award-info":[{"award-number":["257505"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ctrv.2021.102296","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T02:28:04Z","timestamp":1632104884000},"page":"102296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group"],"prefix":"10.1016","volume":"100","author":[{"given":"Edit","family":"Bardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e L.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira C.","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy A.","family":"Ruble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Burgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"den Hoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart G.P.","family":"Koot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Szonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Hamish","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontien C.M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Effinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Bresters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2013a population-based study","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102296_b0010","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. (Eds.), SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"issue":"7","key":"10.1016\/j.ctrv.2021.102296_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102296_b0020","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2008.21.1953","article-title":"Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings","volume":"27","author":"Diller","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102296_b0025","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.297.24.2705","article-title":"Medical assessment of adverse health outcomes in long-term survivors of childhood cancer","volume":"297","author":"Geenen","year":"2007","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102296_b0030","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102296_b0035","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2011.01.049","article-title":"Survivors of childhood cancer have increased risk of gastrointestinal complications later in life","volume":"140","author":"Goldsby","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102296_b0040","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ijc.30198","article-title":"Gastrointestinal and liver disease in Adult Life After Childhood Cancer in Scandinavia: A population-based cohort study","volume":"139","author":"Asdahl","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2021.102296_b0045","doi-asserted-by":"crossref","unstructured":"Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YKK, et al. Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database Syst Rev 2019;4(4):Cd008205.","DOI":"10.1002\/14651858.CD008205.pub3"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102296_b0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/pbc.22265","article-title":"Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group","volume":"54","author":"Castellino","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102296_b0055","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(08)70279-1","article-title":"Part I: Liver function in oncology: biochemistry and beyond","volume":"9","author":"Field","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102296_b0060","series-title":"Late effects of childhood cancer","first-page":"85","article-title":"Hepatic complications","author":"Hudson","year":"2004"},{"key":"10.1016\/j.ctrv.2021.102296_b0065","doi-asserted-by":"crossref","unstructured":"Hudson M. Late gastrointestinal and hepatic effects. In: Schwartz CL HW, Constine LS, Ruccione KS, editors. Survivors of childhood and adolescent cancer. A multidisciplinary approach. Second edition ed. New York: Springer 2005. p. 181-202.","DOI":"10.1007\/3-540-26498-1_12"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"issue":"7156","key":"10.1016\/j.ctrv.2021.102296_b0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bmj.317.7156.465","article-title":"Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group","volume":"317","author":"Bero","year":"1998","journal-title":"BMJ"},{"issue":"8883","key":"10.1016\/j.ctrv.2021.102296_b0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0140-6736(93)92244-N","article-title":"Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations","volume":"342","author":"Grimshaw","year":"1993","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102296_b0085","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1001\/jama.282.24.2358","article-title":"The need for perspective in evidence-based medicine","volume":"282","author":"Woolf","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2021.102296_b0090","unstructured":"Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers, Version 5.0. Monrovia, CA: Children's Oncology Group; October 2018. Available from URL: http:\/\/www.survivorshipguidelines.org\/."},{"key":"10.1016\/j.ctrv.2021.102296_b0095","unstructured":"Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. Dutch Childhood Oncology Group; 2010. Available from URL: http:\/\/www.skion.nl\/."},{"key":"10.1016\/j.ctrv.2021.102296_b0100","unstructured":"Skinner R, Wallace WHB, Levitt GA. United Kingdom Children's Cancer Study Group Late Effects Group. Therapy based long term follow up. Practice statement; 2005. Available from URL: http:\/\/www.cclg.org.uk\/."},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/pbc.25310","article-title":"The views of European clinicians on guidelines for long-term follow-up of childhood cancer survivors","volume":"62","author":"Brown","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2021.102296_b0110","doi-asserted-by":"crossref","unstructured":"Wallace WH, Thompson L, Anderson RA. Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance. BMJ 2013;346:f1190.","DOI":"10.1136\/bmj.f1190"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102296_b0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bjh.15166","article-title":"Investigation and management of a raised serum ferritin","volume":"181","author":"Cullis","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2014.08.058","article-title":"Ferritin in decompensated cirrhosis: iron or inflammation?","volume":"62","author":"Ryan","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pbc.24445","article-title":"A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"60","author":"Kremer","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2021.102296_b0130","doi-asserted-by":"crossref","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089.","DOI":"10.1136\/bmj.i2089"},{"issue":"7454","key":"10.1016\/j.ctrv.2021.102296_b0135","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102296_b0140","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1161\/01.CIR.0000063682.20730.A5","article-title":"American College of Cardiology\/American Heart Association clinical practice guidelines: Part I: where do they come from?","volume":"107","author":"Gibbons","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/hep.30176","article-title":"Serum alanine aminotransferase elevations in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study","volume":"69","author":"Green","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2012.07.009","article-title":"Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: prevalence and risk factors","volume":"49","author":"Mulder","year":"2013","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102296_b0155","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pbc.22202","article-title":"Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis","volume":"53","author":"Jagt","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.bmt.1705887","article-title":"Abnormal liver enzymes two years after haematopoietic stem cell transplantation in children: prevalence and risk factors","volume":"41","author":"Bresters","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102296_b0165","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1651-2227.1998.tb01507.x","article-title":"Disease of the liver following bone marrow transplantation in children: incidence, clinical course and outcome in a long-term perspective","volume":"87","author":"Frisk","year":"1998","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00042737-200402000-00006","article-title":"Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy","volume":"16","author":"Ho","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2021.102296_b0175","doi-asserted-by":"crossref","unstructured":"Locasciulli A, Testa M, Valsecchi MG, Vecchi L, Longoni D, Sparano P, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997;90(9):3799-805.","DOI":"10.1182\/blood.V90.9.3799"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102296_b0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bmt.1702532","article-title":"Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients","volume":"26","author":"Tom\u00e1s","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102296_b0185","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0190","first-page":"425","article-title":"Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis","volume":"16","author":"Saleh","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","article-title":"Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update","volume":"11","author":"Shiha","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0205","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hep.22109","article-title":"Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease","volume":"47","author":"Kim","year":"2008","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102296_b0210","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102296_b0215","doi-asserted-by":"crossref","unstructured":"Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009;136(2):477-85.e11.","DOI":"10.1053\/j.gastro.2008.10.052"},{"key":"10.1016\/j.ctrv.2021.102296_b0220","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388-402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10.1016\/j.ctrv.2021.102296_b0225","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406-60.","DOI":"10.1016\/j.jhep.2018.03.024"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0230","first-page":"98","article-title":"Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss","volume":"26","author":"Luyckx","year":"2000","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1089-3261(05)70099-4","article-title":"Alcohol-induced liver disease","volume":"4","author":"Maddrey","year":"2000","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0240","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/beem.2002.0225","article-title":"Obesity and liver disease","volume":"16","author":"Scheen","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ctrv.2021.102296_b0250","doi-asserted-by":"crossref","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135(6):1924-34, 34.e1-4.","DOI":"10.1053\/j.gastro.2008.09.011"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0255","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102296_b0260","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1055-9965.EPI-14-0292","article-title":"Characterization of transfusion-derived iron deposition in childhood cancer survivors","volume":"23","author":"Ruccione","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbmt.2009.09.011","article-title":"Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy","volume":"16","author":"Busca","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102296_b0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/bmt.2008.99","article-title":"Iron overload in hematopoietic cell transplantation","volume":"41","author":"Majhail","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MPH.0000000000000444","article-title":"Iron Overload in Survivors of Childhood Cancer","volume":"38","author":"Schempp","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102296_b0280","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1399-3046.2008.00983.x","article-title":"Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Chotsampancharoen","year":"2009","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0285","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bmt.2016.205","article-title":"Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study","volume":"52","author":"Sirvent","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2021.102296_b0290","series-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]","article-title":"Chapter 3 Iron overload and chelation","author":"Porter","year":"2014"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102296_b0295","first-page":"184","article-title":"Iron chelation for iron overload secondary to transfusions of packed red blood cells","volume":"12","author":"Cid","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0300","first-page":"128","article-title":"Guidelines on haemovigilance of post-transfusional iron overload","volume":"11","author":"Remacha","year":"2013","journal-title":"Blood Transfus"},{"key":"10.1016\/j.ctrv.2021.102296_b0305","first-page":"014","article-title":"Assessment of iron overload and chelation therapy in adult inpatients with sickle cell disease","volume":"4","author":"Bohm","year":"2018","journal-title":"Int Arch Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2010.03.001","volume":"53","author":"EASL clinical practice guidelines for HFE hemochromatosis","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.24330","article-title":"Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Bacon","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474086.2018.1420473","article-title":"Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform","volume":"11","author":"Valent","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102296_b0325","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/bmt.2014.276","article-title":"Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children","volume":"50","author":"Pillon","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0330","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000268404","article-title":"Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology","volume":"27","author":"de Buy","year":"2010","journal-title":"Dig Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0335","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1089-3261(03)00069-2","article-title":"Benign liver neoplasms","volume":"6","author":"Mortele","year":"2002","journal-title":"Clin Liver Dis"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102296_b0340","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/cncr.11452","article-title":"Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome","volume":"97","author":"Bouyn","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0345","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28137","article-title":"Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload","volume":"67","author":"Cattoni","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2021.102296_b0350","doi-asserted-by":"crossref","unstructured":"Masetti R, Colecchia A, Rondelli R, Martoni A, Vendemini F, Biagi C, et al. Benign hepatic nodular lesions after treatment for childhood cancer. J Pediatr Gastroenterol Nutr 2013;56(2):151-5.","DOI":"10.1097\/MPG.0b013e31826f7660"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102296_b0355","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/petr.12091","article-title":"Focal nodular hyperplasia of the liver in children after hematopoietic stem cell transplantation","volume":"17","author":"Masetti","year":"2013","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0360","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2214\/AJR.11.7690","article-title":"Incidence and etiology of new liver lesions in pediatric patients previously treated for malignancy","volume":"199","author":"Smith","year":"2012","journal-title":"Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102296_b0365","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bmt.2008.304","article-title":"Focal nodular hyperplasia of the liver following hematopoietic SCT","volume":"43","author":"Sudour","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102296_b0370","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002470050768","article-title":"Hepatic regenerating nodules: a mimic of recurrent cancer in children","volume":"30","author":"Brisse","year":"2000","journal-title":"Pediatr Radiol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0375","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2214\/AJR.12.9734","article-title":"Dynamic MRI findings and clinical features of benign hypervascular hepatic nodules in childhood-cancer survivors","volume":"201","author":"Yoo","year":"2013","journal-title":"Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102296_b0380","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mpo.10231","article-title":"Liver histology after current intensified therapy for childhood acute lymphoblastic leukemia: microvesicular fatty change and siderosis are the main findings","volume":"40","author":"Halonen","year":"2003","journal-title":"Med Pediatr Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102296_b0385","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/archdischild-2014-307985","article-title":"Paediatric non-alcoholic fatty liver disease: a practical overview for non-specialists","volume":"100","author":"Mann","year":"2015","journal-title":"Arch Dis Child"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102296_b0390","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2021.102296_b0395","first-page":"S186","article-title":"Non-alcoholic fatty liver disease","volume":"17","author":"Angulo","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102296_b0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-016-0393-5","article-title":"Obesity and Metabolic Syndrome Among Adult Survivors of Childhood Leukemia","volume":"17","author":"Gibson","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102296_b0405","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/jayao.2015.0036","article-title":"Metabolic Health in Childhood Cancer Survivors: A Longitudinal Study in a Long-Term Follow-Up Clinic","volume":"5","author":"Gunn","year":"2016","journal-title":"J Adolesc Young Adult Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:18Z","timestamp":1759656498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":81,"alternative-id":["S0305737221001444"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102296","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102296"}}